Biopharma companies are actively working to enhance their sustainability efforts to increase the emphasis on long-term value creation, stakeholder engagement, and forward-looking disclosures. To support these efforts, the Biopharma Sustainability Roundtable (BSRT) partnered with CECP’s CEO Investor Forum, to co-host the first sector-specific CEO-Investor Forum that took place on June 7-8, 2021.
Event Highlights
CEOs leveraged CECP’s Long-Term Plan Framework and the Biopharma Investor ESG Communications Guidance to tailor the content of their presentations for this investor-focused event.
Leading up to the event, BSRT and the CEO Investor Forum released an executive report, “Integrating Sustainability and Long-term Planning for the Biopharma Sector,” and a companion practitioner’s guide to support biopharma CEOs and their teams as they prepared their sustainable long-term plans for investors.
Learn More
June 7th-8th, 2021
The Biopharma Sustainability Roundtable (BSRT) and CECP’s CEO Investor Forum invite you to join nine leading leading biopharma CEOs for the first-ever sector-specific Biopharma CEO Investor Forum, June 7-8, 2021. CEOs from Catalent, GlaxoSmithKline, Incyte, Merck & Co., Moderna, Pfizer, Sanofi, Takeda, and UCB will share their Long-Term Plans for sustainable value creation with leading institutional investors and the wider stakeholder community.
May 13, 2021
Sandor Schoichet and Thomas Scheiwiller discuss the drive toward integrating environmental, social, and governance (ESG) topics into biopharma business planning, and communicating effectively about ESG performance with capital markets.
Listen on Soundcloud or Apple Podcasts